Stocks making the biggest moves premarket: Paramount, Warner Bros., Accenture, Novo & more

Paramount and Warner Bros. Discovery rose 5.8% and 7%, respectively, after reports that Paramount discussed settling a California lawsuit blocking their proposed merger. Accenture gained more than 6% after announcing an Anthropic partnership, with the companies committing at least $1 billion to AI capacity. Coinbase added over 4% as bitcoin reached $85,229.44, while Novo fell nearly 5% on investor disappointment with its long-term obesity-drug growth targets.

Analysis

The media spread is primarily a regulatory-optionality trade, not yet a fundamental rerating. If the transaction path clears, WBD likely has greater percentage upside because a buyer can extract meaningful overlap savings across distribution, marketing, technology and content spend from its lower-margin asset base; PSKY carries more of the financing, execution and political-risk burden. Over the next 1-3 months, every legal filing, remedy proposal or closing timetable matters more than subscriber or advertising data; a prolonged review would rapidly erode the current premium and revive WBD balance-sheet concerns.

ACN's AI partnership should be viewed as a booking-conversion question rather than evidence of near-term margin expansion. The firm can monetize model selection, integration, governance and managed-services work regardless of which foundation model wins, but the announced capacity commitment could initially dilute utilization or raise subcontractor/cloud costs before revenue scales. The key 6-18 month upside is that AI projects migrate from low-value pilots to enterprise-wide implementation, improving ACN's backlog mix; falsification would be flat consulting bookings, worsening utilization, or incremental operating-margin pressure at the next two earnings reports.

COIN remains a high-beta expression of crypto liquidity and tokenization policy rather than a clean bitcoin proxy. A sustained bitcoin advance should lift retail engagement, custody balances and transaction revenue with operating leverage, but the stock's recent sensitivity leaves it exposed to a fast reversal in bitcoin, ETF flows, or tokenized-equity implementation delays. NVO's reaction is more consequential: a long-dated pipeline target does little to defend the multiple if the market concludes obesity-market pricing, adherence, or competitive differentiation deteriorate before new launches arrive; near-term prescription trends and trial readouts dominate the 2035 narrative.

Contrarian view: ARHS's upgrade-driven move is least investable absent evidence that customer-acquisition spending produces profitable order growth. In a discretionary furnishings category, brand awareness can raise sales while worsening CAC and promotional intensity, particularly if housing turnover remains subdued.

Key Decisions for Investors

• Trade WBD/PSKY as a conditional merger spread: long WBD versus short PSKY in equal dollar amounts only after independently verifying the transaction structure, consideration and regulatory timetable. Target a 1-3 month catalyst window; exit if the parties cannot define acceptable California remedies or if financing terms widen materially.
• Accumulate ACN on post-headline consolidation rather than chase a gap-up, with a 6-12 month horizon. Size modestly until management quantifies AI-related bookings, capacity spending and margin effect; reduce if FY guidance implies utilization deterioration or more than 50-100 bps of incremental margin pressure.
• Use COIN only as a tactical 2-6 week crypto-liquidity long, preferably through defined-risk call spreads rather than unhedged equity after a sharp rally. Pair against a partial long BTC exposure or use a bitcoin stop below the recent breakout zone; the thesis fails if ETF flows reverse and retail volumes do not follow price.
• Remain underweight NVO versus diversified pharma until obesity prescription growth and next-generation trial data demonstrate that pipeline value can offset competitive price pressure. A constructive reversal requires evidence of sustained volume growth without a material cut to obesity revenue or margin expectations.
• Do not initiate ARHS from the analyst upgrade alone. Set an alert for improving comparable sales, gross-margin stability and disclosed marketing payback at the next earnings release; absent those data, the upside is narrative-driven while downside remains tied to housing and discretionary demand.